Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD
Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD

NCT04535882

CompletedN/A

Sponsor: Showa Inan General Hospital

Conditions: LRG Levels

Interventions: serum leucine-rich alpha-2 glycoprotein (LRG) levels

Countries: Japan

We attempt to examine the association between serum leucine-rich alpha-2 glycoprotein (LRG) levels and endoscopic activity in patients with possible ulcerative colitis (UC) or Crohn's disease (CD) to determine whether LRG was a predicting marker for UC or CD.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* Patients whom possible UC or Crohn disease was suspected

Exclusion Criteria:

* other autoimmune diseases
* acute or chronic renal failure
* chronic heart diseases
* liver cirrhosis
* cancer
* acute or chronic systemic infections
* ischemic colitis
Locations (1)
  • Komagane, Nagano, Japan